116 related articles for article (PubMed ID: 29802897)
1. Evaluating prodrug characteristics of a novel anticoagulant fusion protein neorudin, a prodrug targeting release of hirudin variant 2-Lys47 at the thrombosis site, by means of in vitro pharmacokinetics.
Dong X; Gu R; Zhu X; Gan H; Liu J; Jin J; Meng Z; Dou G
Eur J Pharm Sci; 2018 Aug; 121():166-177. PubMed ID: 29802897
[TBL] [Abstract][Full Text] [Related]
2. Predicting the metabolic characteristics of neorudin, a novel anticoagulant fusion protein, in patients with deep vein thrombosis.
Dong X; Meng Z; Gu R; Zhu X; Gan H; Jin J; Liu J; Dou G
Thromb Res; 2020 Oct; 194():121-134. PubMed ID: 32788104
[TBL] [Abstract][Full Text] [Related]
3. Development, validation, and clinical pharmacokinetic application of ultra-performance liquid chromatography/tandem mass spectrometry method for simultaneously determining a novel recombinant hirudin derivative (Neorudin) and its active metabolite in human serum.
Dong X; Meng Z; Jin J; Gu R; Dou G
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Sep; 1063():204-213. PubMed ID: 28886579
[TBL] [Abstract][Full Text] [Related]
4. The Antithrombotic Effect of Recombinant Neorudin on Thrombi.
Liu YB; Zhang L; Zhou XC; Zhou Y; Liu Y; Zheng C; Xu X; Geng PP; Hao CH; Zhao ZY; Wu CT; Jin JD
Drug Des Devel Ther; 2022; 16():1667-1678. PubMed ID: 35677424
[TBL] [Abstract][Full Text] [Related]
5. A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss.
Sheffield WP; Eltringham-Smith LJ; Bhakta V
BMC Biotechnol; 2018 Apr; 18(1):21. PubMed ID: 29621998
[TBL] [Abstract][Full Text] [Related]
6. Construction and functional evaluation of hirudin derivatives with low bleeding risk.
Zhang C; Yu A; Yuan B; Dong C; Yu H; Wang L; Wu C
Thromb Haemost; 2008 Feb; 99(2):324-30. PubMed ID: 18278181
[TBL] [Abstract][Full Text] [Related]
7. Recombinant Neorudin for the Prevention of Deep-Vein Thrombosis After Spinal-Cord Injury.
Liu YB; Liu Y; Zhang L; Zhou XC; Ren BY; Zheng C; Hao CH; Wang WT; Xia X; Zhou GQ; Wu CT; Jin JD
Drug Des Devel Ther; 2023; 17():2523-2535. PubMed ID: 37641688
[TBL] [Abstract][Full Text] [Related]
8. Engineering a "three-in-one" hirudin prodrug to reduce bleeding risk: A proof-of-concept study.
Zhu Y; Han HH; Zhai L; Yan Y; Liu X; Wang Y; Lei L; Wang JC
J Control Release; 2021 Oct; 338():462-471. PubMed ID: 34481024
[TBL] [Abstract][Full Text] [Related]
9. Expression, purification and characterization of multigram amounts of a recombinant hybrid HV1-HV2 hirudin variant expressed in Saccharomyces cerevisiae.
Lehman ED; Joyce JG; Bailey FJ; Markus HZ; Schultz LD; Dunwiddie CT; Jacobson MA; Miller WJ
Protein Expr Purif; 1993 Jun; 4(3):247-55. PubMed ID: 8518563
[TBL] [Abstract][Full Text] [Related]
10. Improving long circulation and procoagulant platelet targeting by engineering of hirudin prodrug.
Han HH; Zhang HT; Wang R; Yan Y; Liu X; Wang Y; Zhu Y; Wang JC
Int J Pharm; 2020 Nov; 589():119869. PubMed ID: 32919000
[TBL] [Abstract][Full Text] [Related]
11. Factor X fusion proteins: improved production and use in the release in vitro of biologically active hirudin from an inactive alpha-factor-hirudin fusion protein.
Guarna MM; Côté HC; Kwan EM; Rintoul GL; Meyhack B; Heim J; MacGillivray RT; Warren RA; Kilburn DG
Protein Expr Purif; 2000 Nov; 20(2):133-41. PubMed ID: 11049737
[TBL] [Abstract][Full Text] [Related]
12. Inhibition by recombinant hirudins of experimental venous thrombosis and disseminated intravascular coagulation induced by tissue factor in rats.
Freund M; Cazenave JP; Courtney M; Degryse E; Roitsch C; Bernat A; Delebassée D; Defreyn G; Maffrand JP
Thromb Haemost; 1990 Apr; 63(2):187-92. PubMed ID: 2363120
[TBL] [Abstract][Full Text] [Related]
13. Point mutations modifying the thrombin inhibition kinetics and antithrombotic activity in vivo of recombinant hirudin.
Degryse E; Acker M; Defreyn G; Bernat A; Maffrand JP; Roitsch C; Courtney M
Protein Eng; 1989 Mar; 2(6):459-65. PubMed ID: 2710782
[TBL] [Abstract][Full Text] [Related]
14. A phase I, single and continuous dose administration study on the safety, tolerability, and pharmacokinetics of neorudin, a novel recombinant anticoagulant protein, in healthy subjects.
Liu Y; Wang M; Dong X; He J; Zhang L; Zhou Y; Xia X; Dou G; Wu CT; Jin J
Pharmacol Res Perspect; 2021 May; 9(3):e00785. PubMed ID: 33957018
[TBL] [Abstract][Full Text] [Related]
15. Construction and in vitro testing of a novel fab-hirudin-based fusion protein that targets fibrin and inhibits thrombin in a factor xa-dependent manner.
Peter K; Gupta A; Nordt T; Bauer S; Runge MS; Bode C
J Cardiovasc Pharmacol; 2003 Aug; 42(2):237-44. PubMed ID: 12883328
[TBL] [Abstract][Full Text] [Related]
16. Two characteristics of a recombinant fusion protein composed of staphylokinase and hirudin: high thrombus affinity and thrombus-targeting release ofanticoagulant activity.
Yu A; Zhang C; Dong C; Yu H; Zhong G; Wang L; Wu C
Sheng Wu Gong Cheng Xue Bao; 2008 Nov; 24(11):1955-61. PubMed ID: 19256345
[TBL] [Abstract][Full Text] [Related]
17. Locally activity-released bifunctional fusion protein enhances antithrombosis and alleviates bleeding risk.
Shi B; Yu A; Liu Y; Li J; Jin J; Dong C; Wu C
J Thromb Thrombolysis; 2007 Dec; 24(3):283-92. PubMed ID: 17487572
[TBL] [Abstract][Full Text] [Related]
18. Thrombolytic and anticoagulant effects of a recombinant staphylokinase-hirudin fusion protein.
Ren K; Gong H; Huang J; Liu Y; Dong Q; He K; Tian L; Zhang F; Yu A; Wu C
Thromb Res; 2021 Dec; 208():26-34. PubMed ID: 34688099
[TBL] [Abstract][Full Text] [Related]
19. Inhibitory role of recombinant neorudin on canine coronary artery thrombosis.
Liu YB; Zhou XC; Liu Y; Zhang L; Zhou Y; Xu X; Zheng C; Zhao ZY; Wu CT; Jin JD
Pharmacol Res Perspect; 2022 Jun; 10(3):e00956. PubMed ID: 35505637
[TBL] [Abstract][Full Text] [Related]
20. Characterization of the postglomerular renal metabolism of lepirudin in healthy volunteers.
Kautzleben M; Stein G; Sperschneider H; Nowak G
Thromb Res; 2004; 113(3-4):187-95. PubMed ID: 15140582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
